Business Description
China Shineway Pharmaceutical Group Ltd
NAICS : 325412
ISIN : KYG2110P1000
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 19.61 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.21 | |||||
Interest Coverage | 174.81 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.93 | |||||
Beneish M-Score | -2.42 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.3 | |||||
3-Year EBITDA Growth Rate | 28.4 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 8.4 | |||||
3-Year Book Growth Rate | 7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 12.12 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.02 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
6-1 Month Momentum % | 8.51 | |||||
12-1 Month Momentum % | 8.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.35 | |||||
Quick Ratio | 2.98 | |||||
Cash Ratio | 2.43 | |||||
Days Inventory | 278.66 | |||||
Days Sales Outstanding | 64.31 | |||||
Days Payable | 139.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 19.1 | |||||
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | 1.83 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.21 | |||||
Operating Margin % | 22.52 | |||||
Net Margin % | 26.24 | |||||
FCF Margin % | 18.88 | |||||
ROE % | 16.26 | |||||
ROA % | 12.22 | |||||
ROIC % | 29.62 | |||||
3-Year ROIIC % | 201.81 | |||||
ROC (Joel Greenblatt) % | 115.76 | |||||
ROCE % | 20.65 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 5.36 | |||||
Forward PE Ratio | 5.02 | |||||
PE Ratio without NRI | 5.34 | |||||
Shiller PE Ratio | 9.12 | |||||
Price-to-Owner-Earnings | 6.11 | |||||
PEG Ratio | 0.45 | |||||
PS Ratio | 1.27 | |||||
PB Ratio | 0.83 | |||||
Price-to-Tangible-Book | 0.86 | |||||
Price-to-Free-Cash-Flow | 7.43 | |||||
Price-to-Operating-Cash-Flow | 6.28 | |||||
EV-to-EBIT | 0.17 | |||||
EV-to-EBITDA | 0.17 | |||||
EV-to-Revenue | 0.06 | |||||
EV-to-FCF | 0.3 | |||||
Price-to-Projected-FCF | 0.4 | |||||
Price-to-Median-PS-Value | 0.54 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.5 | |||||
Price-to-Graham-Number | 0.48 | |||||
Price-to-Net-Current-Asset-Value | 1.05 | |||||
Price-to-Net-Cash | 1.73 | |||||
Earnings Yield (Greenblatt) % | 588.24 | |||||
FCF Yield % | 13.46 | |||||
Forward Rate of Return (Yacktman) % | 22.6 |